nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Psychotic Disorders"

 

Long-Acting Injectable Antipsychotics Cut Suicide Death Risk in Half
June 1, 2021   

In a recent population-based cohort study of patients with schizophrenia who received oral antipsychotics (OAPs), data from the Taiwan National Health Insurance Research Database was analyzed. Within this cohort, the study examined risk of suicide in those patients who switched to long-acting injectable antipsychotics compared to those who remained on OAPs...
 Continue reading (Members only)
Youth With ADHD May Have Increased Risk for Psychotic Disorders
March 8, 2021   

In a recent meta-analysis of 12 studies and 1.85 million participants, an increased risk of psychotic disorder was associated with a diagnosis of attention deficit hyperactivity disorder during childhood compared to participants without attention deficit hyperactivity disorder during childhood....
 Continue reading
Switching Antipsychotics to Ameliorate Weight Gain
February 23, 2021   

Atypical antipsychotics are often associated with detrimental metabolic changes that may influence treatment adherence, quality of life, and mortality. In this meta-analysis, the authors investigated the benefits of switching from one antipsychotic to another with less propensity for metabolic changes...
 Continue reading
Clozapine to Reduce Aggression in Patients With Schizophrenia and Conduct Disorder
February 11, 2021   

The first head-to-head comparison study of clozapine, olanzapine, and haloperidol in the treatment of violent schizophrenia patients with and without conduct disorder was recently conducted. Patients who had a history of being physically assaultive...
 Continue reading (Members only)
Antipsychotics and the Gut Microbiome: A 2-Way Street?
December 19, 2020   

Increasingly, interest has been gathering about the role of the gut microbiome in psychiatry. The microbiome is the collection of microorganisms, such as bacteria, found in the gut and varies from one individual to the next due to a plethora of factor...
 Continue reading (Members only)
FDA Committees Vote in Favor of a Combination of Olanzapine and Samidorphan
October 14, 2020   

Two advisory committees, the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the US Food and Drug Administration have voted in favor of ALKS 3831, a combination of olanzapine and samidorphan. The...
 Continue reading
New Schizophrenia Treatment Guidelines Released by APA
September 14, 2020   

The American Psychiatric Association (APA) has just released its latest guidelines for the treatment of patients with schizophrenia. These new guidelines are the first APA schizophrenia guidelines to be published in over a decade. During that 10+ year interim, there have been many advancements in...
 Continue reading
Olanzapine/Samidorphan Combo Found to Reduce Antipsychotic-Induced Weight Gain
September 1, 2020   

The combination of olanzapine, a dopamine D2 receptor antagonist, and samidorphan, an opioid receptor antagonist, is being developed for the treatment of schizophrenia and bipolar I disorder. Despite its efficacy, olanzapine is associated with significant weight gain and adverse metabolic effects that limit its clinical utility as a monotherapy. The combination of olanzapine and samidorphan has been shown to...
 Continue reading (Members only)
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
Consensus Statement on Use of Antipsychotic Blood Levels
June 23, 2020   

It has been known that the quantification of antipsychotic levels in blood, known as therapeutic monitoring can be helpful in determining appropriate therapeutic dosing, and augmentation for treatment. It can be a useful tool for antipsychotics to manage challenging clinical scenarios, such as lack of therapeutic response, relapse, or adverse drug reactions (ADRs) related to antipsychotic treatment, especially...
 Continue reading (Members only)
123456789
Top of Page